Skip to main content
NACFC 2026 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded Session
Recorded Session
Livestreamed Session
Livestreamed Session
Session is Ticketed (Add-on Session through Registration)
Session is Ticketed (Add-on Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF

Lunch & Learn

IMI

CLIN

LL12-- Lessons from Immunotherapeutics from Other Airways Diseases

Saturday, October 10, 2026
12:30 PM - 2:00 PM EDT
Food Available for Session Attendees
As Highly Effective Modulator Therapy (HEMT) transforms the CF landscape, persistent airway inflammation, infection, and structural lung disease remain significant challenges for many patients. Meanwhile, the broader respiratory field has seen rapid therapeutic advances targeting neutrophilic and type 2 inflammatory pathways in asthma, non-CF bronchiectasis, and Nontuberculous Mycobacteria (NTM) lung disease. This interactive Lunch and Learn will bring together three experts working at the interface of these fields to examine how immuno-therapeutics developed for other airways diseases may be leveraged for CF. Speakers will address biologics in CF-associated type 2 inflammation, DPP1/cathepsin antagonists targeting neutrophilic airway damage, and emerging therapies for NTM and non-CF bronchiectasis. Brief presentations will be followed by a moderated panel discussion exploring where these therapeutic strategies converge and what they mean for the future of CF care.

Learning Objectives: At the conclusion of this session, attendees will be able to:

  • Evaluate the rationale and emerging evidence for repurposing asthma biologics targeting type 2 inflammation in people with CF.


  • Describe the mechanism of DPP1/cathepsin inhibition and assess its potential to address neutrophil-mediated airway injury in CF.


  • Identify therapeutic strategies from the non-CF bronchiectasis and NTM treatment landscape that may inform novel anti-inflammatory approaches in CF.